SCHEMBL5570586

SCHEMBL5570586

Cc1c(C(=O)NC2CCCCC2)cc(-c2cc(C(F)(F)F)ccc2F)n1C[C@@H]1CCCC[C@@H]1O

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.60
CNR2 P34972 3/20 0.42
CRHR1 P34998 11/20 0.42
ALDH1A1 P00352 2/20 0.42
CRHR2 Q13324 2/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
CRHBP P24387 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FAAH O00519 2/20 0.40
ABHD12 Q8N2K0 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916898 1.00 CNR1 (0.60) CNR1CNR2CRHR1ALDH1A1CRHR2
SCHEMBL13717335 1.00 CNR1 (0.60) CNR1CNR2CRHR1ALDH1A1CRHR2
SCHEMBL3916901 1.00 CNR1 (0.60) CNR1CNR2CRHR1ALDH1A1CRHR2
SCHEMBL13717645 0.91 CNR1 (0.70) CNR1CNR2CRHR1
SCHEMBL3927443 0.91 CNR1 (0.73) CNR1CRHR1CRHR2
SCHEMBL13717286 0.91 CNR1 (0.73) CNR1CRHR1CRHR2
SCHEMBL13717289 0.91 CNR1 (0.73) CNR1CRHR1CRHR2
SCHEMBL3927445 0.91 CNR1 (0.73) CNR1CRHR1CRHR2
SCHEMBL3928194 0.89 CNR1 (0.66) CNR1CNR2CRHR1ALDH1A1CRHR2
SCHEMBL3922337 0.89 CNR1 (0.63) CNR1CNR2CRHR1ALDH1A1CRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167129-A1 Novel CB 1 receptor inverse agonists HOFFMANN-LA ROCHE INC. 2004-08-26 US claimed
US-7294644-B2 CB 1 receptor inverse agonists HOFFMANN-LA ROCHE INC. (US) 2007-11-13 US disclosed
US-20040167129-A1 Novel CB 1 receptor inverse agonists HOFFMANN-LA ROCHE INC. 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167129-A1 Novel CB 1 receptor inverse agonists CNR1, CNR2, ARRB1 CNR1 1/4885CNR2 2/4885CRHR1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.